UT 105
Alternative Names: SARD UT-105; UT-105Latest Information Update: 18 Jun 2021
At a glance
- Originator University of Tennessee Research Foundation
- Developer Oncternal Therapeutics, Inc.; University of Tennessee Research Foundation
- Class Antiandrogens; Small molecules
- Mechanism of Action Androgen receptor antagonists; Androgen receptor degradation enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Triple negative breast cancer
Most Recent Events
- 10 Apr 2021 Preclinical trials in Triple negative Breast cancer in USA (unspecified route) before April 2021
- 10 Apr 2021 Efficacy and pharmacodynamics data from a preclinical trial in triple-negative Breast cancer presented at the 112th Annual Meeting of the American Association for Cancer Research (AACR-2021)
- 31 Dec 2020 Oncternal Therapeutics has patent protection for SARD ligands and methods of use thereof in USA, Australia, Japan, and Russia